Semaglutide has received significant attention in the past few years — and with it, a substantial amount of misinformation. This article explains, from a clinical perspective, what semaglutide actually is, how it works, who it is appropriate for, and what patients should understand about its role in a broader weight management approach.
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist — a class of medications that mimic the action of glucagon-like peptide-1, a naturally occurring gut hormone. GLP-1 is secreted by cells in the small intestine in response to food intake. It coordinates a multi-system response that affects blood sugar regulation, insulin secretion, gastric emptying, and appetite.
Semaglutide was originally developed for type 2 diabetes management. Its weight loss effects emerged as a significant secondary finding in diabetes trials. Higher-dose semaglutide formulations were subsequently developed and approved specifically for chronic weight management.
What does it actually do?
Appetite reduction via central nervous system effects. GLP-1 receptors are expressed in the hypothalamus, the brain region that regulates hunger and satiety. Semaglutide activates these receptors, reducing the hunger drive and increasing the perceived satisfaction from smaller amounts of food. Most patients on semaglutide report that they simply think about food less — cravings diminish and portion control requires less effort.
Slowed gastric emptying. Semaglutide slows the rate at which the stomach empties into the small intestine. This extends the feeling of fullness after eating and reduces post-meal blood sugar spikes.
Improved insulin sensitivity and glucose regulation. Semaglutide stimulates insulin secretion in a glucose-dependent manner (it does not lower blood sugar in the absence of elevated glucose) and suppresses inappropriate glucagon release. The result is better blood sugar regulation and — over time — improved insulin sensitivity.
Reduced visceral fat. The combination of reduced caloric intake and improved insulin sensitivity results in preferential reduction of visceral (abdominal) fat, which carries the highest metabolic risk.
What the clinical trials show
The STEP trials — the clinical program that evaluated semaglutide at the weight management dose — showed average weight reductions of 14.9% to 17.4% of body weight over sixty-eight weeks, significantly exceeding outcomes from lifestyle intervention alone. These results are clinically meaningful.
What is less often discussed: the trial participants also underwent intensive lifestyle intervention. The medication was not the only variable. The combination of semaglutide with structured diet and activity changes produced the results the trials reported. Medication in isolation produces more modest outcomes.
What happens when you stop
This is the part that does not make most headlines: most patients regain a substantial portion of lost weight after discontinuing semaglutide. The STEP 4 trial showed significant weight regain after withdrawal.
This reflects a fundamental reality: semaglutide addresses the appetite and insulin signaling components of weight regulation, but it does not fix the underlying metabolic drivers. When the medication is removed, those drivers — often including hormonal imbalances, persistent insulin resistance, disrupted sleep, and elevated cortisol — reassert themselves.
This is why we offer semaglutide as one component of a metabolic program, not as a standalone prescription. Our approach addresses the metabolic context within which the medication operates, with the goal of creating enough underlying change that patients can eventually reduce or discontinue medication without full weight regain.
Is semaglutide right for you?
Candidacy for GLP-1 therapy is determined after a complete metabolic evaluation — not a questionnaire.
Learn About Medical Weight LossWho is an appropriate candidate?
GLP-1 receptor agonists are clinically appropriate for adults with:
- BMI ≥ 30 (obesity), or
- BMI ≥ 27 with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea)
They require a prescription. They require an in-person clinical evaluation before prescribing. We do not prescribe weight loss medications online.
There are also contraindications — personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, among others — that must be screened for at consultation.
Common side effects
The most common side effects of semaglutide are gastrointestinal: nausea, vomiting, diarrhea, constipation. These are most pronounced in the early weeks of treatment and typically improve as the dose is titrated upward gradually. Starting at a low dose and increasing slowly is standard protocol — it exists to minimize these effects.
More serious adverse effects are uncommon but real and should be reviewed at your clinical consultation.
What semaglutide is not
It is not a cure for obesity. It is a pharmacological tool that, within the right metabolic and behavioral framework, produces meaningful and sustained weight reduction in appropriate candidates. The framework matters as much as the medication.
It is not appropriate for everyone. Candidacy requires clinical evaluation.
It is not appropriate as a shortcut to a lifestyle intervention. Patients who expect the medication to do all the work consistently see less durable results than those who use it as a support within a structured program.
The right way to think about it
Semaglutide is one of the most clinically effective weight management tools that has emerged in recent years. It deserves serious consideration for appropriate patients. It also deserves honest discussion of its limitations, the importance of the broader metabolic context, and the need for structured lifestyle engagement alongside it.
If you are interested in whether semaglutide might be appropriate for you, the starting point is a clinical consultation and a metabolic assessment — not an online prescription service.
*Information in this article is educational and does not constitute medical advice. GLP-1 medications require a prescription and in-person clinical evaluation. Individual results vary significantly.*
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.